Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + cisplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
QL1706 + cisplatin + paclitaxel is an investigational chemo-immunotherapy combination regimen being evaluated for the treatment of cervical cancer. QL1706 (also known as iparomlimab and tuvonralimab) is a novel bifunctional 'Mabpair' biologic product consisting of a mixture of an anti-PD-1 IgG4 antibody and an anti-CTLA-4 IgG1 antibody, both produced from a single cell line. This regimen combines dual immune checkpoint inhibition with standard cytotoxic chemotherapy agents: cisplatin, a platinum-based DNA alkylator, and paclitaxel, a microtubule-stabilizing taxane. It is primarily being studied as a neoadjuvant therapy for patients with early-stage (FIGO 2018 stage IB1–IB3) cervical cancer to improve pathological complete response rates prior to surgery, and as a first-line treatment for recurrent or metastatic disease.
- Other names
- QL1706 + Cisplatin/PaclitaxelQL1706 + cisplatin + paclitaxel Neoadjuvant Therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNACTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + cisplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + cisplatin + paclitaxel.